Biopharmaceuticals

Financial funding
#BioCentriq #Biopharmaceuticals #Cytiva #Funding #National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) #Partnership

NIIMBL funding awarded to bring gene therapies to market faster 

Cytiva and BioCentriq, a new Jersey-based cell and gene therapy contract development and manufacturing organisation (CDMO), have been awarded funding from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership whose mission is to accelerate biopharmaceutical innovation.  Viral clearance is a key regulatory requirement… Read More

#News

AI drug
#Artificial intelligence (AI) #Biopharmaceuticals #Collaboration #Influenza #Poolbeg Pharma

AI-led programme identifies multiple influenza drug targets 

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a breakthrough in its influenza AI Programme with CytoReason.   Poolbeg has been working with CytoReason since March 2022. Poolbeg’s disease progression data from influenza human challenge… Read More

#News

#Biopharmaceuticals #Inoviem Scientific #Personalised medicine

Podcast on enhancing genetically guided personalised medicine

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with… Read More

#News

#Biopharmaceuticals #Immunology / Virology & Vaccines #Investment #invoX Pharma #mRNA #mRNA-based vaccines #Next generation sequencing #Sino Biopharmaceutical

pHion to progress its lead program into the clinic 

invoX Pharma, a UK-based wholly-owned subsidiary of Sino Biopharmaceutical, with an advancing pipeline of innovative products, has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.   pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. Read More

#Business & Investment #News

Touchlight exterior view London
#Biopharmaceuticals #DNA #Genetics #Plasmid DNA

New London facility exceeds global plasmid DNA demand 

Touchlight, a company providing DNA services and manufacturing enzymes, has completed the redevelopment and expansion of its UK manufacturing facility in London, UK.   The expanded facility’s manufacturing capacity has tripled and is now capable of producing more than 8kg a year. This exceeds the current, but growing,… Read More

#News

Science connection and networking
#Biopharmaceuticals #BioTrinity #Comment #Events #Funding #Investment #Life sciences

Reflecting on BioTrinity 2023  

BioTrinity 2023 marked the 17th annual edition of BioTrinity and took place in London, UK from Tuesday 25 April to Wednesday 26 April. DDW’s Megan Thomas spoke with attendees, and comments on the event.    Fundraising and investment   Coming out of a global pandemic, in-person events initially… Read More

#Exclusive Content

#Biopharmaceuticals #Collaboration #Contract Research Organisations (CROs) #Cryo-EM #Drug research #Immunology #Oncology

What’s next for this integrated drug discovery collaboration? 

Galapagos and NovAliX have entered a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organisation. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and… Read More

#News

#Biopharmaceuticals #Biotechnology #Epidemiology #Infectious diseases #Novel candidates

Destiny Pharma publishes landmark XF-73 clinical data  

Destiny Pharma, a UK-based clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, has published landmark XF-73 clinical data in the US peer reviewed journal Infection Control & Hospital Epidemiology.    The paper was published by Dr. Julie Mangino… Read More

#News

#Biopharmaceuticals #Cell and gene therapy #Life sciences

Can characterisation industrialise cell and gene therapy?  

The cell and gene therapy (CGT) market is rapidly expanding, and projections suggest it will reach over $90B by 2023. With a maturing clinical pipeline, many FDA-approved treatments are on the horizon. The biopharma industry must industrialise cell and gene therapy manufacturing to bring these life-saving therapies to a… Read More

#Exclusive Content #Opinion

#Biopharmaceuticals #Cell and gene therapy #Covid-19 #Drug development

Overcoming inefficiencies to improve access to cell and gene therapy 

The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Lauren Collison, PhD, Senior VP, Operations & Site Head, KBI Biopharma, reflects.  … Read More

#Exclusive Content #Opinion

#Autoimmune disease #Biopharmaceuticals #Covid-19 #Long Covid #Multiple sclerosis #Neurodegenerative disorders

€25 million to support clinical developments against long Covid

GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of Covid-19, (PASC, post-Covid or long Covid), has entered into a credit agreement for a total amount of up to €25 million with the… Read More

#News

Influenza
#Acute inflammatory conditions #Biopharmaceuticals #Human trials #Immunomodulators #Infectious diseases #Influenza

New results for severe influenza and inflammatory conditions 

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions.   POLB 001… Read More

#News

#Automated workflows #Automation #Automation / robotics #Biopharma #Biopharmaceuticals #Lab automation #Lab technology #Personalised medicine

The push towards lab automation in biopharma

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Peter Walters, Director Advanced Therapies, CRB, and Grace Linton, Director Process Architecture, CRB about automation within laboratory settings and its effect on the pharmaceutical industry. RA: How are labs utilising automated systems in… Read More

#Exclusive Content

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top 20 global biopharma companies report 5.4% growth

The top 20 biopharmaceutical companies have recorded a growth of 5.4% in aggregate market capitalisation – from $3.43 trillion on December 31, 2021 to $3.61 trillion on December 31, 2022.  According to analytics company GlobalData, 11 companies indicated double-digit growth, with four companies – Merck & Co… Read More

#Business & Investment #Editor's Choice #Market Reports #News

#AI #Biopharma #Biopharmaceuticals #Comment #DNA #Lab automation #SLAS2022 #Synthetic biology

Podcast: The impact of synthetic biology and collaboration in pharma

This is the latest episode of the free DDW podcast. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Why synthetic biology is the next big thing for biopharma” and “Collaborative spirit helps drive innovation”. ‘Can synthetic biology save… Read More

#News